Journals Pulmonary Pharmacology & Thera...

Pulmonary Pharmacology & Therapeutics
Tingting Ying, Yulong Yu, Qimin Yu, Gang Zhou, Lingyang Chen, Yixiao Gu, Lijun Zhu, Haifeng Ying, Minjuan Chen
BACKGROUND: Interferon gene stimulator (Sting) is an indispensable adaptor protein that plays a crucial role in acute lung injury (ALI) induced by sepsis, and the PARP-1/NLRP3 signaling pathway may be an integral component of the inflammatory response mediated by Sting. However, the regulatory role of Sting in the PARP-1/NLRP3 pathway in ALI remains insufficiently elucidated. METHODS: Using lipopolysaccharide (LPS) to induce ALI in C57BL/6 mice and HUVEC cells, an in vivo and in vitro model was established...
June 5, 2024: Pulmonary Pharmacology & Therapeutics
Janiana Raíza Jentsch Matias de Oliveira, Mayara Alves Amorim, Vitor Hélio de Souza Oliveira, Daniela de Almeida Cabrini, Michel Fleith Otuki, Claudia Martins Galindo, Bruna Barbosa da Luz, Maria Fernanda de Paula Werner, João Batista Calixto, Eunice André
Although TRPV1 receptors play an essential role in the adverse effects on the airways following captopril treatment, there is no available evidence of their involvement in treatment regimens involving repeated doses of captopril. Comparing the difference in these two treatment regimens is essential since captopril is a continuous-use medication. Thus, this study explored the role of the transient receptor potential vanilloid 1 (TRPV1) in the effects of captopril on rat airways using two treatment regimens. Airway resistance, bronchoalveolar lavage (BAL), and histological and immunohistochemical analyses were conducted in rats administered with single or repeated doses of captopril...
May 30, 2024: Pulmonary Pharmacology & Therapeutics
Natalie R Rose, Ashritha R Chalamalla, Bryan A Garcia, Stefanie Krick, Jonathan Bergeron, Hossein Sadeghi, Dennis E Schellhase, Kevin J Ryan, Alexander E Dowell, Edward P Acosta, Jennifer S Guimbellot
Elexacaftor, tezacaftor, ivacaftor (ETI) is a CFTR modulator combination approved for use in ∼90% of people with cystic fibrosis (pwCF) over 2 years old. While most pwCF tolerate this therapy well, some are intolerant to standard dosing, and others show little response. Clinical providers may adjust ETI dosing to combat these issues, but these adjustments are not well guided by pharmacokinetic evidence. Our post-approval study aimed to describe pharmacokinetic variability of ETI plasma concentrations in 15 participants who were administered a standard or reduced dose...
May 24, 2024: Pulmonary Pharmacology & Therapeutics
Alan Santos-Mena, Oscar E González-Muñiz, Yolanda M Jacobo-Delgado, Bruno Rivas-Santiago
Over the past few decades, there has been extensive research on the use of vitamin D as an adjunctive therapy in the treatment and prevention of tuberculosis. In vitro studies have provided valuable insights into the mechanisms by which vitamin D activates the immune response to combat Mycobacterium tuberculosis. These encouraging findings have spurred clinical investigations globally to assess the effectiveness of vitamin D as a preventive measure and as an adjunctive treatment for tuberculosis. However, the results from these clinical studies have been contradictory, with some demonstrating clear efficacy while others report only modest or no activity...
May 7, 2024: Pulmonary Pharmacology & Therapeutics
François Rony, Mauro Cortellini, Alessandro Guasconi, Kusum S Mathews, Annalisa Piccinno, Gianluigi Poli, Frédéric Vanhoutte, Jelle Klein
INTRODUCTION: Use of propellants with high global warming potential (such as HFA-134a) for pressurised metered-dose inhalers (pMDIs) is being phased down. Switching to dry-powder inhalers may not be clinically feasible for all patients; an alternative is reformulation using propellants with low global warming potential. The combination of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) is available for asthma or chronic obstructive pulmonary disease via pMDI using HFA-134a as propellant...
April 23, 2024: Pulmonary Pharmacology & Therapeutics
Ji-Yong Moon, Sang Hyuk Kim, Youlim Kim, Hyun Lee, Chin Kook Rhee, Seung Won Ra, Chang Youl Lee, Joo Hun Park, Yong Bum Park, Kwang Ha Yoo
BACKGROUND: A suboptimal peak inspiratory flow rate (PIFR) in dry-powder inhaler (DPI) users can lead to insufficient therapeutic effects in the treatment of chronic obstructive pulmonary disease (COPD). However, few data on the prevalence of and factors associated with suboptimal PIFR in Korean patients with COPD are available. METHODS: We conducted a cross-sectional study of patients with COPD who had been using DPIs for more than three months. PIFR was measured using an In-Check DIAL G16 device...
April 9, 2024: Pulmonary Pharmacology & Therapeutics
Atsushi Torii, Masahide Oki, Hiroatsu Iida, Arisa Yamada, Yoshihito Kogure, Chiyoe Kitagawa, Hideo Saka
BACKGROUND AND OBJECTIVE: Other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD) are rare but well-known diseases that manifest during or after methotrexate (MTX) administration. Limited information is available on the clinical characteristics of OIIA-LPD of the lung because only a few cases have been reported. Thus, we aimed to assess the incidence and prognosis of patients with OIIA-LPD of the lung. METHODS: Patients with OIIA-LPD of the lung treated at our institution between January 2008 and July 2020 were retrospectively analysed...
March 11, 2024: Pulmonary Pharmacology & Therapeutics
Yi Yu, Dengcan Yang, Qianqian Wang, Jian Li
BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is a severe condition with high mortality and morbidity rates. Evidence on the effectiveness of pharmacological interventions for ARDS treatment is limited. Recent studies suggest that aspirin may prevent ARDS development, but its efficacy in established ARDS is uncertain. METHODS: We enrolled patients with ARDS using data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database. Primary outcomes were 30- and 90-day mortality rates and length of ICU stay...
March 7, 2024: Pulmonary Pharmacology & Therapeutics
Ruiming Zhao, Bingbing Xie, Xin Wang, Xinran Zhang, Yanhong Ren, Chen Wang, Huaping Dai
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive and fatal lung disease lacking effective therapeutics. Treatment with pirfenidone or nintedanib is recommended for patients to delay the progression of their disease. Adverse reactions caused by anti-fibrosis drugs can sometimes interrupt treatment and even change the progression of the disease. OBJECTIVE: This study aimed to investigate the clinical use, adverse reactions, tolerability of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and the efficacy of antifibrotic therapy in a real world...
March 2024: Pulmonary Pharmacology & Therapeutics
Huijuan Zhang, Jianli Qiu, Qianyi Zhao, Yong Zhang, Haitao Zheng, Ziying Dou, Yongbin Yan
Pulmonary fibrosis is a complex disease that can occur in a variety of clinical settings. The Zinc Finger and BTB Domain Containing 16 (Zbtb16) is a transcription factor and has not been studied in pulmonary fibrosis. Lung tissues from rats which were treated with bleomycin and Tanshinone IIA (Tan IIA) were collected for mRNA sequencing. Zbtb16, a differentially expressed gene, was screened. Using adeno-associated virus to knock down Zbtb16 in rats, it was found that the lung index and the content of hydroxyproline in lung tissue were decreased...
March 2024: Pulmonary Pharmacology & Therapeutics
L Jayaram, P T King, J Hunt, M Lim, C Park, E Hu, L Dousha, P Ha, J B Bartlett, A M Southcott, S Muruganandan, S Vogrin, M A Rees, O M Dean, C A Wong
BACKGROUND: High dose N acetylcysteine (NAC), a mucolytic, anti-inflammatory and antioxidant agent has been shown to significantly reduce exacerbations, and improve quality of life in placebo controlled, double blind randomised (RCT) studies in patients with COPD, and in an open, randomised study in bronchiectasis. In this pilot, randomised, double-blind, placebo-controlled study, we wished to investigate the feasibility of a larger clinical trial, and the anti-inflammatory and clinical benefits of high dose NAC in bronchiectasis...
March 2024: Pulmonary Pharmacology & Therapeutics
Tomasz Dębowski, Monika Marko, Barbara Rogala, Paweł Majak, Rafał Pawliczak
INTRODUCTION: Extrafine formulation of beclomethasone/formoterol fixed combination (BDP/F pMDI HFA) is approved for both fixed maintenance and maintenance and reliever therapy (MART) of asthma, and recent data has proven that BDP/F pMDI HFA maintenance and reliever therapy is an effective alternative to other regimens. OBJECTIVE: This study aimed to assess the level of asthma control in a real-life setting in adult patients using extrafine BDP/F pMDI HFA fixed combination in a pressurized metered-dose inhaler (pMDI) as fixed maintenance dosing as well as maintenance and maintenance and reliever therapy...
March 2024: Pulmonary Pharmacology & Therapeutics
Shuyun Chen, Tiantian Zhao, Shiguang Xie, Xuan Wan
Pulmonary fibrosis is a progressive and debilitating lung disease characterized by the excessive accumulation of extracellular matrix (ECM) components within the lung parenchyma. However, the underlying mechanism remains largely elusive, and the treatment options available for pulmonary fibrosis are limited. Interleukin 5 receptor, alpha (IL5RA) is a well-established regulator of eosinophil activation, involved in eosinophil-mediated anti-parasitic activities and allergic reactions. Recent studies have indicated additional roles of IL5RA in lung epithelium and fibroblasts...
January 6, 2024: Pulmonary Pharmacology & Therapeutics
Zemin Chen, Haixiong Tang, Sudan Gan, Changyun Yang, Shiyue Li, Jing Li, Lihong Yao
BACKGROUND: Loss of E-cadherin in the airway epithelial cells is a critical contributor to the development of ALI/ARDS. Yet the underlying mechanisms are largely unknown. Increasing evidences have revealed the significance of ferroptosis in the pathophysiological process of ALI/ARDS. The aim of this study was to investigate the role of ferroptosis in dysregulation of airway epithelial E-cadherin in ALI/ARDS. METHODS: BALB/c mice were subjected to intratracheal instillation of lipopolysaccharide (LPS) to establish an ALI model...
December 26, 2023: Pulmonary Pharmacology & Therapeutics
Xiaoxing Wang, Wenwen Du, Dan Zhang, Wenhui Chen, Xianbo Zuo
BACKGROUND: Lung transplant recipients (LTRs) have a higher risk of hospitalization and mortality due to COVID-19 compared with the immunocompetent population. The use of nirmatrelvir/ritonavir (NR), an effective oral treatment for COVID-19, is quite challenging due to its potent drug-drug interactions with immunosuppressants and azole antifungals. As there are few clinical reports of the use of NR in LTRs, we measured tacrolimus levels in patients receiving NR in our hospital to improve safety when prescribing NR...
December 6, 2023: Pulmonary Pharmacology & Therapeutics
Colleen McEvoy, Rahul Argula, Sandeep Sahay, Shelley Shapiro, Christina Eagan, Anthony J Hickey, Chad Smutney, Chris Dillon, Thomas Winkler, Brittany N Davis, Meredith Broderick, Charles Burger
Tyvaso DPI is a drug-device combination therapy comprised of a small, portable, reusable, breath-powered, dry powder inhaler (DPI) for the delivery of treprostinil. It is approved for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Tyvaso DPI utilizes single-use prefilled cartridges to ensure proper dosing. Unlike nebulizer devices, administration of Tyvaso DPI is passive and does not require coordination with the device. The low-flow rate design results in targeted delivery to the peripheral lungs due to minimal drug loss from impaction in the oropharynx...
December 2023: Pulmonary Pharmacology & Therapeutics
Gabriela Santos, André Fabiano, Patrícia Caetano Mota, Inês Rodrigues, Diogo Carvalho, Natália Melo, Hélder Novais-Bastos, André Terras Alexandre, Conceição Souto Moura, Susana Guimarães, José Miguel Pereira, André Carvalho, António Morais
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause that is associated with radiological and/or histological features of usual interstitial pneumonia (UIP). A mean survival of 2-5 years was reported previously to the advent of antifibrotics. According to clinical trials, nintedanib and pirfenidone induce a significant delay in functional decline, with a favorable impact on survival. METHODS: A real-life retrospective and longitudinal study was conducted to assess the efficacy and tolerability of antifibrotics in IPF patients, between January 2014 and December 2020...
December 2023: Pulmonary Pharmacology & Therapeutics
Magnus Aurivillius, Artur Bednarczyk, Marek Kokot, Jonathan Madriaga, Jie Mei, Kathryn Collison, Raulin Surujbally, James Archbell, Vidya Joshi, Michael Gillen
INTRODUCTION: The climate crisis poses an immediate threat to human health and well-being, demanding urgent adaptions across sectors, including healthcare. The development of pressurized metered dose inhalers (MDIs) with greater sensitivity to the climate emergency using novel propellants with lower global warming potentials (GWPs), but comparable pharmacokinetic (PK) parameters to currently marketed MDIs, is a vital step toward reducing the impact of healthcare for respiratory disorders on climate change...
December 2023: Pulmonary Pharmacology & Therapeutics
Lily Zheng, Mohammad H Alshaer, Charles Peloquin, Veena Venugopalan, Hassan M Alnuaimat, Maureen Converse
BACKGROUND: The impact of extracorporeal membrane oxygenation (ECMO) on the pharmacokinetics/dynamics (PK/PD) of beta-lactam antibiotics have not been well studied in general, but cefepime specifically has the least amount of data. We aimed to investigate whether ECMO alters the PK of cefepime in adult intensive care unit (ICU) patients. METHODS: This single-center, retrospective case-control study evaluated cefepime therapeutic drug monitoring (TDM) results from ECMO patients that were matched 1:1 with TDM results in non-ECMO patients for drug regimen and renal function...
November 24, 2023: Pulmonary Pharmacology & Therapeutics
Silvano Dragonieri, Vitaliano Nicola Quaranta, Andrea Portacci, Giovanna Elisiana Carpagnano
Inhaled corticosteroids, along with beta2-agonists and anti-muscarinics, represent the cornerstone of asthma treatment. Although the advent of monoclonal antibodies has dramatically changed severe asthma management, there are still patients ineligible or with poor response to biologics. Moreover, high costs associated with monoclonal antibodies prescription are still an open issue, leading clinicians to carefully assess cost-benefit ratio before their administration. From this perspective, the use of single-inhaler Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium in patients with severe asthma could not only improve their clinical and functional performance, but also postpone biologic prescription, with positive repercussions on healthcare costs...
November 24, 2023: Pulmonary Pharmacology & Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.